BHV-1

BHV-1 is a novel oncolytic viral immunotherapy based on bovine herpesvirus type 1 (BoHV-1), currently in preclinical development by 3io Therapeutics in partnership with McMaster University. The therapy is designed to treat KRAS-mutated cancers, including lung, colorectal, and pancreatic cancers. Unlike traditional oncolytic viruses that rely on direct viral replication and tumor lysis, BHV-1 functions as an immuno-stimulating platform whose efficacy is primarily driven by the stimulation of anti-tumor immunity. The virus is non-pathogenic in humans and has demonstrated the potential for systemic intravenous (IV) delivery, maintaining its efficacy even in the presence of neutralizing antibodies. Preclinical studies have shown that BHV-1 can significantly boost the efficacy of immune checkpoint inhibitors. The platform allows for monotherapy with minimal genetic engineering, although cassette payload insertion is also possible for enhanced therapeutic effects.

Other names

bovine herpesvirus type 1BoHV-1BoHV1BoHV 1